221 related articles for article (PubMed ID: 15926079)
21. Immunocytochemical study on internalization of anti-carbohydrate monoclonal antibodies.
Kusano A; Ohta S; Shitara K; Hanai N
Anticancer Res; 1993; 13(6A):2207-12. PubMed ID: 8297135
[TBL] [Abstract][Full Text] [Related]
22. Activation of complement by monoclonal antibodies that target cell-associated β₂-microglobulin: implications for cancer immunotherapy.
Pokrass MJ; Liu MF; Lindorfer MA; Taylor RP
Mol Immunol; 2013 Dec; 56(4):549-60. PubMed ID: 23911412
[TBL] [Abstract][Full Text] [Related]
23. Immunochemical detection of a small cell lung cancer-associated ganglioside (FucGM1) antigen in serum.
Vangsted AJ; Clausen H; Kjeldsen TB; White T; Sweeney B; Hakomori S; Drivsholm L; Zeuthen J
Cancer Res; 1991 Jun; 51(11):2879-84. PubMed ID: 1851663
[TBL] [Abstract][Full Text] [Related]
24. Small cell lung cancer is not associated with the presence of anti-fucosyl-GM1 ganglioside autoantibodies reactive in immunoenzymatic test.
Adler G; Pacuszka T; Lewartowska A; Rowinska E; Oblakowski P; Panasiewicz M
Lung Cancer; 2001 Dec; 34(3):383-5. PubMed ID: 11714535
[TBL] [Abstract][Full Text] [Related]
25. Levels of cell membrane CD59 regulate the extent of complement-mediated lysis of human melanoma cells.
Brasoveanu LI; Altomonte M; Fonsatti E; Colizzi F; Coral S; Nicotra MR; Cattarossi I; Cattelan A; Natali PG; Maio M
Lab Invest; 1996 Jan; 74(1):33-42. PubMed ID: 8569195
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of membrane complement inhibitor expression (CD46, CD55, CD59) by siRNA sensitizes tumor cells to complement attack in vitro.
Geis N; Zell S; Rutz R; Li W; Giese T; Mamidi S; Schultz S; Kirschfink M
Curr Cancer Drug Targets; 2010 Dec; 10(8):922-31. PubMed ID: 20879979
[TBL] [Abstract][Full Text] [Related]
27. Vaccine therapy for small cell lung cancer.
Krug LM
Semin Oncol; 2004 Feb; 31(1 Suppl 1):112-6. PubMed ID: 14981589
[TBL] [Abstract][Full Text] [Related]
28. Apoptosis induction of human lung cancer cell line in multicellular heterospheroids with humanized antiganglioside GM2 monoclonal antibody.
Nakamura K; Hanibuchi M; Yano S; Tanaka Y; Fujino I; Inoue M; Takezawa T; Shitara K; Sone S; Hanai N
Cancer Res; 1999 Oct; 59(20):5323-30. PubMed ID: 10537316
[TBL] [Abstract][Full Text] [Related]
29. Detection of a ganglioside antigen associated with small cell lung carcinomas using monoclonal antibodies directed against fucosyl-GM1.
Nilsson O; Brezicka FT; Holmgren J; Sörenson S; Svennerholm L; Yngvason F; Lindholm L
Cancer Res; 1986 Mar; 46(3):1403-7. PubMed ID: 3002616
[TBL] [Abstract][Full Text] [Related]
30. Human interferon-gamma enhances expression of ganglioside GM2 on human lung cancer cells and their susceptibility for antiganglioside GM2 monoclonal antibody-dependent cellular cytotoxicity.
Hanibuchi M; Nishioka Y; Yanagawa H; Yano S; Parajuli P; Bando M; Sone S
Oncol Res; 2000; 12(4):173-9. PubMed ID: 11341466
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic efficacy of mouse-human chimeric anti-ganglioside GM2 monoclonal antibody against multiple organ micrometastases of human lung cancer in NK cell-depleted SCID mice.
Hanibuchi M; Yano S; Nishioka Y; Yanagawa H; Kawano T; Sone S
Int J Cancer; 1998 Nov; 78(4):480-5. PubMed ID: 9797137
[TBL] [Abstract][Full Text] [Related]
32. Beta-glucan enhanced killing of renal cell carcinoma micrometastases by monoclonal antibody G250 directed complement activation.
Sier CF; Gelderman KA; Prins FA; Gorter A
Int J Cancer; 2004 May; 109(6):900-8. PubMed ID: 15027124
[TBL] [Abstract][Full Text] [Related]
33. Characterization of a proapoptotic antiganglioside GM2 monoclonal antibody and evaluation of its therapeutic effect on melanoma and small cell lung carcinoma xenografts.
Retter MW; Johnson JC; Peckham DW; Bannink JE; Bangur CS; Dresser K; Cai F; Foy TM; Fanger NA; Fanger GR; Woda B; Rock KL
Cancer Res; 2005 Jul; 65(14):6425-34. PubMed ID: 16024647
[TBL] [Abstract][Full Text] [Related]
34. T cell-independent B cell response to self-monosialogangliosides: primary response monoclonal antibodies.
Alfonso M; Vázquez AM; Carr A; Haerslev T; Fernández LE; Lanio ME; Alvarez C; Zeuthen J; Pérez R
Hybridoma; 1995 Jun; 14(3):209-16. PubMed ID: 7590782
[TBL] [Abstract][Full Text] [Related]
35. Functional assessment in vitro of human-complement-dependent antibody-induced cytotoxicity of neoplastic cells.
Brezicka F; Einbeigi Z; Bergman B
Cancer Immunol Immunother; 2000 Jul; 49(4-5):235-42. PubMed ID: 10941906
[TBL] [Abstract][Full Text] [Related]
36. New serum markers for small-cell lung cancer. I. The ganglioside fucosyl-GM1.
Vangsted A; Drivsholm L; Andersen E; Pallesen T; Zeuthen J; Wallin H
Cancer Detect Prev; 1994; 18(3):221-9. PubMed ID: 8076384
[TBL] [Abstract][Full Text] [Related]
37. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis.
Golay J; Zaffaroni L; Vaccari T; Lazzari M; Borleri GM; Bernasconi S; Tedesco F; Rambaldi A; Introna M
Blood; 2000 Jun; 95(12):3900-8. PubMed ID: 10845926
[TBL] [Abstract][Full Text] [Related]
38. Lysis of human tumor cell lines by canine complement plus monoclonal antiganglioside antibodies or natural canine xenoantibodies.
Helfand SC; Hank JA; Gan J; Sondel PM
Cell Immunol; 1996 Jan; 167(1):99-107. PubMed ID: 8548851
[TBL] [Abstract][Full Text] [Related]
39. The inhibitory effect of CD46, CD55, and CD59 on complement activation after immunotherapeutic treatment of cervical carcinoma cells with monoclonal antibodies or bispecific monoclonal antibodies.
Gelderman KA; Blok VT; Fleuren GJ; Gorter A
Lab Invest; 2002 Apr; 82(4):483-93. PubMed ID: 11950905
[TBL] [Abstract][Full Text] [Related]
40. Effect of a chimeric anti-ganglioside GM2 antibody on ganglioside GM2-expressing human solid tumors in vivo.
Fukumoto H; Nishio K; Ohta S; Hanai N; Fukuoka K; Ohe Y; Sugihara K; Kodama T; Saijo N
Int J Cancer; 1999 Aug; 82(5):759-64. PubMed ID: 10417777
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
